Adjuvant capesitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial
- Heikki Joensuu (Keynote speaker)
- Kellokumpu-Lehtinen, P. (Keynote speaker)
- Riikka Huovinen (Keynote speaker)
- Jukkola-Vuorinen, A. (Keynote speaker)
- Mina Tanner (Keynote speaker)
- Riitta Kokko (Keynote speaker)
- Päivi Auvinen (Keynote speaker)
- Outi Lahdenperä (Keynote speaker)
- Kenneth Villman (Keynote speaker)
- Paul Nyandoto (Keynote speaker)
- Greger Nilsson (Keynote speaker)
- Marja Murashev (Keynote speaker)
- Paula Poikonen-Saksela (Keynote speaker)
- Petri Bono (Keynote speaker)
- Vesa Kataja (Keynote speaker)
- Henrik Lindman (Keynote speaker)
Aktiviteetti: Kutsuttu esitelmä